Gliosarcoma Market Report 2026

Gliosarcoma Market Overview

• Gliosarcoma market size has reached to $1.25 billion in 2025 • Expected to grow to $1.6 billion in 2030 at a compound annual growth rate (CAGR) of 5% • Growth Driver: Rising Incidence Of Brain Tumors And The Growing Need For Gliosarcoma Treatment • Market Trend: Advancements In Wearable Technology For Cancer Treatment And Monitoring • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Gliosarcoma Market?

Gliosarcoma refers to a rare and aggressive brain tumor that consists of both glial and sarcomatous tissue, typically occurring in the cerebral hemisphere. They are used for studying tumor biology and developing treatment strategies for glioblastoma and other brain malignancies. The main diagnosis methods for gliosarcoma include imaging techniques, histopathological examination, and biomarker testing. Imaging techniques are non-invasive methods, such as MRI, CT, and PET scans, used to visualize internal structures of the body for diagnosing abnormalities. It offers various types of treatments such as surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy and is used by hospitals, cancer research institutes, and specialty clinics.

What Is The Gliosarcoma Market Growth Forecast?

The gliosarcoma market size is expected to see strong growth in the next few years. It will grow to $1.6 billion in 2030 at a compound annual growth rate (CAGR) of 5.0%. The growth in the forecast period can be attributed to increased rare cancer research funding, precision diagnostics development, improved treatment protocols, expansion of molecular testing, collaboration between research centers. Major trends in the forecast period include increased research into rare brain tumors, growing use of molecular diagnostics, expansion of multimodal treatment strategies, rising focus on tumor biology studies, improved diagnostic accuracy.

Global Gliosarcoma Market Segmentation

1) By Diagnosis Method: Imaging Techniques, Histopathological Examination, Biomarker Testing 2) By Treatment Type: Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Immunotherapy 3) By End-User: Hospitals, Cancer Research Institutes, Specialty Clinics Subsegments: 1) By Imaging Techniques: Magnetic Resonance Imaging (MRI), Computed Tomography (CT) Scan, Positron Emission Tomography (PET) Scan 2) By Histopathological Examination: Hematoxylin and Eosin (H&E) Staining, Immunohistochemistry (IHC), Electron Microscopy 3) By Biomarker Testing: IDH Mutation Testing, MGMT Promoter Methylation Testing, ATRX Mutation Testing, TP53 Mutation Analysis

What Is The Driver Of The Gliosarcoma Market?

The increasing incidence of brain tumors is expected to propel the growth of the gliosarcoma market going forward. A brain tumor is an abnormal growth of cells in the brain, which can be benign or malignant and may cause symptoms like headaches, seizures, and vision problems. The incidence of brain tumors is rising due to improved diagnostic technologies, increased awareness, and potential environmental and lifestyle factors contributing to higher exposure to risk factors. Gliosarcoma treatment is essential for brain tumors because it targets this aggressive and rare cancer, aiming to manage symptoms, prolong survival, and improve the patient’s quality of life. For instance, in February 2025, according to Dementia Australia, an Australia-based non-profit organization, approximately 433,300 Australians are living with dementia, with this number expected to rise to 812,500 by 2054. Additionally, younger-onset dementia affects around 29,000 people in 2025, with projections indicating an increase to 41,000 by 2054. Therefore, the increasing incidence of brain tumors is driving the growth of the gliosarcoma industry.

Key Players In The Global Gliosarcoma Market

Major companies operating in the gliosarcoma market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., Bio-Rad Laboratories Inc., Carl Zeiss AG, Elekta AB, Novocure Ltd., ImmunityBio Inc., Immatics Biotechnologies, Karyopharm Therapeutics Inc., Kintara Therapeutics Inc., Aveta Biomics Inc., Vigeo Therapeutics Inc.

Global Gliosarcoma Market Trends and Insights

Major companies operating in the gliosarcoma market are focusing on developing technologically advanced products, such as wearable devices, to provide convenient, continuous monitoring of health and activity data, offering real-time insights and enhancing user engagement with their wellness goals. Wearable devices are electronic gadgets designed to be worn on the body that monitor, track, or enhance various aspects of health, fitness, or daily activities. For instance, in November 2024, Novocure Ltd., a UK-based oncology company, announced the U.S. Food and Drug Administration (FDA) approval for the use of Head Flexible Electrode (HFE) transducer arrays alongside Optune Gio for treating adult patients with glioblastoma multiforme (GBM). The Optune Gio is a portable, wearable device that uses non-invasive wearable arrays to provide tumor-treating fields (TTFields), which apply physical forces to the electrically charged parts of dividing cancer cells to stop their fast division. The new HFE arrays are 50% thinner and one-third lighter than the ceramic discs found in the existing Optune Gio arrays because they are composed of a flexible polymer substance. This improves patient comfort and use.

What Are Latest Mergers And Acquisitions In The Gliosarcoma Market?

In October 2024, Merck & Co. Inc., a US-based pharmaceutical company, acquired Modifi Biosciences for a deal of $1.3 billion. With this acquisition, Merck aims to strengthen its portfolio in glioblastoma and cancer therapies by advancing innovative treatments and expanding its expertise in oncology. Modifi Biosciences is a US-based company that develops treatments for glioblastoma.

Regional Outlook

North America was the largest region in the gliosarcoma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Gliosarcoma Market?

The gliosarcoma market consists of revenues earned by entities by providing services such as molecular diagnostics, clinical trials and research, palliative care services, rehabilitation, and recovery support. The market value includes the value of related goods sold by the service provider or included within the service offering. The gliosarcoma market also includes sales of diagnostic kits, research reagents, and patient monitoring devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Gliosarcoma Market Report 2026?

The gliosarcoma market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the gliosarcoma industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.